A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM ID:3430931

Launched by IRCCS CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI · Feb 14, 2023

Keywords

ClinConnect Summary

The MAINSTREAM clinical trial is exploring new ways to diagnose and treat a condition called Primary Progressive Aphasia (PPA), which affects a person's ability to use language due to changes in the brain. The goal of the study is to test a combined treatment that uses a method called transcranial direct current stimulation (tDCS) along with personalized language training. This study aims to find out if this new approach can be more effective for people with mild stages of PPA compared to a placebo (a treatment with no active effect).

To participate in this trial, individuals must be diagnosed with PPA, specifically in its mild form, and be native Italian speakers. Participants will receive either the active treatment or the placebo, along with language therapy. The study is currently recruiting participants of all genders, and it's important to note that those with certain medical or psychiatric conditions, or developmental disorders, will not be eligible to join. This trial represents an exciting opportunity to improve care and support for individuals living with PPA and their families.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis PPA according to the current clinical criteria (Gorno-Tempini et al., 2011);
• • Mild PPA defined using the Progressive Aphasia Severity Scale (PASS);
• • Italian native speakers.
• Exclusion Criteria:
• • Presence of developmental disorders;
• • Presence of any medical or psychiatric illness that could interfere in completing assessments;
• • Presence of any medical condition that represents a contraindication to tDCS.